Foundayo Lawsuit [2026 Update] – Severe Side Effects & Eligibility

The Foundayo Lawsuit is an Active Lawsuit

Contact Our Team

Foundayo (orforglipron) is an oral GLP-1 for weight loss that received FDA approval in April 2026. Foundayo is under scrutiny because it may be associated with severe side effects that may not adequately be reflected on the drug’s label. As part of the drug-approval and monitoring processes, the FDA has required Eli Lilly (Foundayo’s manufacturer) to examine Foundayo’s possible heart, gastrointestinal, and liver effects.

Foundayo may be the subject of future lawsuits related to the drug’s side effects. As the drug was released in April 2026, mass litigation involving Foundayo patients has not occurred. However, litigation against Eli Lilly, the drug’s manufacturer, may occur as more people experience side effects that impact their health. King Law will be tracking Foundayo lawsuits as they evolve.

About the Foundayo Lawsuit:

Foundayo Litigation Updates and Case Developments

The updates below describe legal and administrative updates about Foundayo, including clinical trials and legal complaints about its safety.

July 17, 2026: Foundayo Prescriptions Top 20k Per Week But Lag Behind the Wegovy Pill

Foudayo has been FDA-approved for over three months. According to market research data, more than 24,000 Foundayo prescriptions were written over the last week (the drug’s 14th week on market). Although prescriptions for Eli Lilly’s weight-loss pill continue to tick up, Foundayo lags far behind Novo Nordisk’s Wegovy pill, which had more than 113,000 prescriptions written in its 14th week on the market.

May 12, 2026: Patients May Not Regain Much Weight When Switching From Injectable GLP-1 to Foundayo, Study Suggests

According to data from a clinical trial study on Foundayo, people who are on an injectable GLP-1 and transition to the oral GLP-1, Foundayo, may not regain much of the weight they had lost. However, the results of the study (Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial) are mixed. Some patients in the study regained about 2 pounds when they switched from a competitor’s injectable GLP-1 to Foundayo. Other patients in the study gained 11 pounds when they transitioned to Foundayo after taking Eli Lilly’s strongest injectable GLP-1 drug. Foundayo is an oral GLP-1 drug, and researchers are still learning about its safety profile.

May 1, 2026: Foundayo Prescribed Over 5,600 Times in Third Week on Market

According to public reports, Eli Lilly’s new GLP-1 pill, Foundayo, was prescribed about 5,612 times in its third week after being launched. Eli Lilly’s competitor also recently launched a new GLP-1 pill (the Wegovy pill), which was prescribed two-thirds more often in its third week on the market. The demand for GLP-1 medications has grown significantly over the past few years. However, many lawsuits have been filed by past GLP-1 patients who believe they suffered from complications (including blindness and gastrointestinal issues) that the GLP-1s may have caused. As Foundayo is also a GLP-1 drug, patients may also experience complications that they allege they were not properly warned about.

May 14, 2026: Some Foundayo Patients May Have Experienced Severe Complications, FDA’s Reporting Dashboard Suggests

According to the FDA’s Adverse Event Reporting System, some patients who took Foundayo may have suffered from side effects and complications. Some of those listed on the FDA dashboard include hair loss, hepatic (liver) failure, nausea, vomiting, diabetic retinopathy, and diarrhea. These events were brought to the FDA’s attention, but investigations need to conducted to determine whether they are related to the patient’s Foundayo use or to other causes.

April 1, 2026: FDA Asks Eli Lilly for More Long-Term Safety Data About Foundayo

As part of the drug-approval process, the FDA has sent a letter to Eli Lilly, asking the company to provide more information about the potential risks of taking Foundayo. According to the FDA’s letter, the FDA does not think it has enough data to know how Foundayo may impact some patients’ hearts and livers. The FDA’s letter also requests more clinical data about the possible complications when taking Foundayo while pregnant or breastfeeding. The FDA has asked Eli Lilly to conduct more clinical trials to understand more about these risks.

April 1, 2026: FDA Approves Foundayo Pill for Weight Loss

The FDA has approved Foundayo (orforglipron) for weight loss when combined with more exercise and fewer calories each day. Foundayo starts at 0.8 mg for 30 days, then may be increased to 2.5 mg if needed. The patient’s Foundayo dose may be increased again to 5.5 mg at least 30 days after the patient starts taking the 2.5 dose. Foundayo will also be offered in higher doses of 9 mg, 14.5 mg, and 17.2 mg. However, patients need to stay on the low-dose tier for at least 30 days before they can increase their Foundayo dose to the next one. The approval announcement says that Foundayo does not have to be taken on an empty stomach like other GLP-1 drugs.

What Is the Foundayo Lawsuit?

Lawsuits are being filed against Eli Lilly, which makes Foundayo and other GLP-1s. Some of those lawsuits accuse Eli Lilly of not being transparent about the safety profile and potential risks patients may experience after taking other GLP-1 drugs the company makes.

Some of the accusations being brought against Eli Lilly include not warning patients that severe liver problems, gastroparesis, ileus, and pancreatitis might occur if patients take a GLP-1. Lawsuits may be filed about Eli Lilly’s new oral GLP-1, Foundayo, if patients believe the drug caused side effects they were not warned about.

Why Isn’t Foundayo Part of the Existing GLP-1 MDL?

There is a multidistrict litigation (MDL) for people alleging injuries from Eli Lilly’s other GLP-1 drugs, such as Mounjaro, Zepbound, and Trulicity. However, people who choose to file lawsuits involving Foundayo cannot join that litigation. That is because Foundayo was released in April 2026, more than two years after MDL 3094 Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation was formed. So, cases involving Foundayo will likely not become part of this litigation. Foundayo lawsuits, like lawsuits against the Wegovy pill, will likely proceed outside of existing MDLs. However, people can still file individual civil lawsuits or join an MDL if one is created involving Foundayo.

Why Are People Filing Foundayo Lawsuits?

Foundayo lawsuits are still in their early stages, and there are no publicly available complaints involving the drug. However, thousands of lawsuits have been filed against Eli Lilly for alleged harm caused by its other GLP-1 drugs. For example, some people who took a GLP-1 that is similar to Foundayo have said they suffered from unexpected gastrointestinal side effects, pancreatitis, liver problems, and cardiovascular events. Some of the claims consumers have brought against Eli Lilly include not being transparent about the safety profiles and failure rates of its GLP-1s.

Foundayo is a new oral GLP-1, and its generic name is orforglipron. Some people who took similar GLP-1s have said they experienced severe side effects that they were not told could occur. Some people are concerned that Eli Lilly has not warned about the severe risks associated with Foundayo either. The FDA has asked Eli Lilly to complete additional testing about Foundayo’s risks.

What Injuries Are Linked to Foundayo?

Foundayo is a new medication, so people are still learning about its potential side effects and severe complications based on the drug being used on a larger scale. However, some of the injuries that people believe are associated with similar GLP-1s include:

• Non-arteritic anterior ischemic optic neuropathy (NAION)
• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Pulmonary aspiration
• Gastroparesis
• Ileus or bowel obstruction requiring surgery
• Necrotizing pancreatitis
• Pancreatic cancer
• Gallbladder cancer
• Gallbladder removal (prior to March 2022)

Some of these complications may require intensive treatment, hospital stays, surgeries, and other interventions to resolve. According to some legal complaints, some GLP-1 patients have died from their complications. Foundayo patients may file lawsuits if they believe taking the medication caused injuries they were not warned about.

How Does Foundayo Cause These Injuries?

Foundayo works by “mimicking” the hormone GLP-1, which regulates processes like hunger, blood sugar levels, and digestion. As a result, Foundayo and products that are similar to it may delay when food contents leave the patient’s stomach.

According to public reports, other GLP-1 products that have worked this way may have slowed or stopped patients’ digestion. Some patients claim they experienced gut paralysis, bowel obstructions, and related complications because of how the GLP-1 impacted their digestion.

Foundayo and other GLP-1 products may also affect how someone’s pancreas and gallbladder function. The pancreas helps to regulate your blood sugar levels. Some studies have suggested that having underlying conditions (like a history of tobacco use and gallstone disease) can increase someone’s risk of developing pancreatitis if they start taking a GLP-1 drug.

Is Foundayo Safe?

When the FDA approved Foundayo, they recognized the overall safety of the drug for treating obesity in specific patients. The FDA approved Foundayo to help eligible patients manage their weight long-term. In clinical trials, some patients without diabetes who took Foundayo lost up to 11.1% of their body weight. However, the medication is new to the market, and the clinical trials may not have captured all the potential side effects. The current warning label for Foundayo includes the following potential risks:

• Thyroid cancer and thyroid tumors
• Acute pancreatitis
• Acute kidney injury
• Hypoglycemia (dangerously low blood sugar)
• Acute gallbladder disease
• Nausea
• Vomiting
• Diarrhea
• Diabetic retinopathy
• Ileus
• Intestinal obstruction
• Severe constipation (includes fecal impaction)

According to the FDA, at least 1,644 adverse event reports have been submitted about patients who took Foundayo as of July 20, 2026. Some of those adverse event reports claim that Foundayo patients experienced liver problems, hair loss, nausea, vomiting, abdominal pain, weight gain, muscle spasms, and dizziness.

The FDA has asked Eli Lilly to conduct additional safety tests for Foundayo and update the FDA with the results. It is important to note that an adverse event report does not mean that the drug caused that event.

FDA Requests More Information on Possible Severe Foundayo Side Effects

Newly approved drugs, like Foundayo, often go through additional critical trials and studies to prove their effectiveness and possible serious side effects. When the FDA approved Foundayo on April 1, 2026, it also said that Eli Lilly had to do additional safety studies on the drug. In the approval letter , the FDA stated that Eli Lilly had to conduct trials or investigations on the following possible Foundayo side effects/adverse events:

• Medullary thyroid carcinoma
• Major adverse cardiovascular events (MACE)
• Drug-induced liver injury (DILI)
• Effects on gastric emptying
• The safety of the drug in pediatric patients
• The safety of the drug for lactating women

Investigations related to Foundayo’s safety are slated to be conducted over the next several months and years. The FDA included timetables in its letter to Eli Lilly.

What Is NAION, and Why Is It Important in Foundayo Lawsuits?

Non-arteritic anterior ischemic optic neuropathy is a rare type of eye stroke that can cause sudden, irreversible blindness. The eye stroke can occur in one or both eyes. Several studies have suggested that people who take GLP-1 products for weight loss may have a higher risk of developing NAION than those who do not. Foundayo is a GLP-1 product, and some are concerned that taking it could raise patients’ risks of losing their eyesight from NAION.

Some people who have taken GLP-1 products that work similarly to Foundayo have suffered from NAION and lost their vision. Some of those patients believe that the GLP-1 product caused NAION, and they claim they were not warned that this could happen. Lawsuits have been filed against Eli Lilly and another GLP-1 manufacturer, accusing the companies of not telling people that NAION may be a potential complication. Patients may file lawsuits about Foundayo, too, if they lost their vision from NAION and were not told that it was a potential complication.

Eli Lilly is a defendant in a multidistrict litigation (MDL) alleging NAION/vision loss from GLP-1 drugs. People have filed lawsuits as part of that litigation, alleging that Mounjaro or Zepbound, two of the company’s GLP-1 drugs, caused them to develop NAION.

Who Qualifies for a Foundayo Lawsuit?

Our law firm is not currently accepting cases from people who took Foundayo and suffered from unexpected and severe gastrointestinal or vision-related complications. However, as more people take the drug and experience side effects, we may start accepting claims.

Some of the possible injuries we are investigating include the following:

• Ileus or bowel obstruction that required surgery
• NAION (blindness caused by an eye stroke)
• Gastroparesis (requires a
• Deep vein thrombosis
• Pulmonary embolism
• Gallbladder removal (must have been done before March 2022)
• Gallbladder cancer
• Pancreatic cancer
• Pulmonary aspiration
• Necrotizing pancreatitis
• Liver conditions
• Cardiac events

As this litigation matures, the injuries we take cases on are likely to change. The above list is an example of some of the injuries that may be listed in future Foundayo lawsuits.

What Compensation Can You Receive in a Foundayo Lawsuit?

Here is some of the compensation you may qualify to receive if you have a valid Foundayo claim and win your case:

• Medical expenses
• Prescription costs
• Diagnostic tests
• Lost wages or earning potential
• Pain and suffering

If you experienced permanent or life-altering complications (such as a cancer diagnosis or blindness), your final settlement may be higher than for less severe diagnoses. However, each settlement is negotiated on a case-by-case basis, and the final settlement reflects the factors at play in that person’s case.

Has a Foundayo Recall or FDA Warning Been Issued?

A recall or warning has not been issued about Foundayo yet. However, the FDA has asked Eli Lilly to be conduct additional studies and submit more information about Foundayo’s safety. As part of postmarketing requirements of the FDA’s drug-approval process, Eli Lilly has been instructed to investigate several adverse events possibly associated with Foundayo.

The possible adverse events included in an April 2026 FDA letter include effects on gastric emptying, major cardiac events, and liver injury. The FDA has also instructed Eli Lilly to investigate possible risks to pediatric patients, lactating mothers and their babies, and mothers and their unborn babies.

How Do Foundayo Lawsuits Compare to Other GLP-1 Drug Lawsuits?

Some legal scholars believe that Foundayo lawsuits may be similar to lawsuits involving other GLP-1s, such as Ozempic, Wegovy, and Rybelsus. Past GLP-1 lawsuits have included claims that Eli Lilly and other drug manufacturers failed to warn patients about gastrointestinal and vision-related complications associated with those drugs. Some of those lawsuits were consolidated into two multidistrict litigations: one involving the NAION allegations and another involving the gastrointestinal claims. Foundayo lawsuits filed in the future may also be consolidated.

How Do I File a Foundayo Lawsuit?

Here are some of the steps involved in filing a Foundayo lawsuit:

1. Contact a seasoned lawyer for a free case evaluation.
2. Gather evidence to support your Foundayo case.
3. Your lawyer investigates your Foundayo claim.
4. Your attorney writes and files the legal complaint against Eli Lilly.
5. Your attorney negotiates a settlement or takes your Foundayo case to trial.

Reputable attorneys understand the legal process and can help strengthen your Foundayo claim and protect your right to fair compensation. They can also help you file your Foundayo lawsuit before the statute of limitations expires.

Is There a Deadline to File a Foundayo Lawsuit?

The deadline (called a statute of limitations) to file a Foundayo lawsuit depends on the applicable state law. States have their own rules about when people can file lawsuits about Foundayo, and some of those rules give people several years to bring a claim. However, the timing of this filing window is highly fact-specific, and there are exceptions that can change the deadline. An attorney can help people identify and meet these filing deadlines.

Foundayo Lawsuit Settlements and Case Value

Foundayo lawsuits are in their early stages, and no settlements have been announced yet. Legal scholars believe that settlements in Foundayo cases will likely reflect the patient’s individual losses, the applicable state law, and other case-specific factors. For example, Foundayo patients who are diagnosed with cancer or permanent disability related to taking Foundayo may qualify for a higher payout. Foundayo patients who experience complications are encouraged to talk to a lawyer about their potential settlement.

King Law Is Investigating Foundayo Lawsuits

King Law is actively investigating claims about Foundayo and severe complications, including gastroparesis, liver disease, cardiac events, NAION, blindness, blood clots, pancreatitis, and gallbladder cancer. We will stay close to this evolving litigation and alert consumers as soon as we start accepting Foundayo lawsuits.

Frequently Asked Questions (FAQs)

List of Sources

King Law adheres to strict editorial standards when creating articles for this site. Here is a list of sources used to write this article.

ClinicalTrials.gov. <a href=”https://clinicaltrials.gov/study/NCT06584916″>A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight (ATTAIN-MAINTAIN).</a> U.S. National Library of Medicine. Accessed 20 July 2026.

DailyMed. <a href=”https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62&audience=consumer”>Foundayo (Orforglipron) Tablets: Consumer Drug Information.</a> U.S. National Library of Medicine. Accessed 20 July 2026.

Eli Lilly and Company. <a href=”https://foundayo.lilly.com/”>Foundayo (Orforglipron) Official Website.</a> Accessed 20 July 2026.

Eli Lilly and Company. <a href=”https://medical.lilly.com/us/products/answers/is-foundayo-orforglipron-associated-with-gastroparesis-317620″>Is Foundayo (Orforglipron) Associated With Gastroparesis?</a> Lilly Medical Information. Accessed 20 July 2026.

Fierce Pharma. <a href=”https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill”>Oral GLP-1 Tracker: Launch Trajectories for Lilly’s Foundayo and Novo’s Wegovy Pill.</a> Fierce Pharma. Accessed 20 July 2026.

U.S. Food and Drug Administration. <a href=”https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf”>Approval Letter: NDA 220934, Orforglipron (Foundayo).</a> 2026.

U.S. Food and Drug Administration. <a href=”https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program”>FDA Approves First New Molecular Entity Under National Priority Voucher Program.</a> Accessed 20 July 2026.

U.S. Food and Drug Administration. <a href=”https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis”>FDA Adverse Event Reporting System (FAERS) Public Dashboard.</a> Accessed 20 July 2026.

Nature Medicine. <a href=”https://www.nature.com/articles/s41591-026-04386-7″>Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial</a>. Nature Medicine, 2026.

Reuters. <a href=”https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-obesity-pill-hits-5612-prescriptions-third-week-after-launch-2026-05-01/”>Lilly’s Obesity Pill Hits 5,612 Prescriptions in Third Week After Launch.</a> 1 May 2026.

ScienceDirect. <a href=”https://www.sciencedirect.com/science/article/abs/pii/S1424390325001449″>Efficacy and Safety of Oral GLP-1 Receptor Agonists for Obesity: A Systematic Review and Meta-analysis.</a> 2025.

Yale Medicine. <a href=”https://www.yalemedicine.org/news/glp-1-weight-loss-pills-what-you-need-to-know”>GLP-1 Weight-Loss Pills: What You Need to Know.</a> Accessed 20 July 2026.